Disease-specific motifs can be identified in circulating nucleic acids from live elk and cattle infected with transmissible spongiform encephalopathies

Paul M. K. Gordon1, Ekkehard Schütz2,3, Julia Beck2, Howard B. Urnovitz2, Catherine Graham4, Renee Clark4, Sandor Dudas4, Stefanie Czub4, Maria Sensen1, Bertram Brenig3, Martin H. Groschup5, Robert B. Church6 and Christoph W. Sensen1,*

1Department of Biochemistry and Molecular Biology, Faculty of Medicine, Sun Center of Excellence for Visual Genomics, University of Calgary, Calgary, AB, Canada T2N 4N1, 2Chronix Biomedical GmbH, Goethealle 8, D-37073 Göttingen, 3Institute of Veterinary Medicine, Georg-August-Universität, Burckhardtweg 2, D-37077 Göttingen, Germany, 4Canadian Food Inspection Agency, Animal Diseases Research Institute, National and OIE BSE Reference Laboratories, Lethbridge, AB, Canada T1J 3Z4, 5Institute for Novel and Emerging Infectious Diseases at the Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Südufer 10, D-17439 Greifswald—Insel Riems, Germany and 6Faculty of Medicine, University of Calgary, Calgary, AB, Canada T2N 4N1

Received August 19, 2008; Revised November 11, 2008; Accepted November 12, 2008

ABSTRACT

To gain insight into the disease progression of transmissible spongiform encephalopathies (TSE), we searched for disease-specific patterns in circulating nucleic acids (CNA) in elk and cattle. In a 25-month time-course experiment, CNAs were isolated from blood samples of 24 elk (Cervus elaphus) orally challenged with chronic wasting disease (CWD) infectious material. In a separate experiment, blood-sample CNAs from 29 experimental cattle (Bos taurus) 40 months post-inoculation with clinical bovine spongiform encephalopathy (BSE) were analyzed according to the same protocol. Next-generation sequencing provided broad elucidation of sample CNAs: we detected infection-specific sequences as early as 11 months in elk (i.e. at least 3 months before the appearance of the first clinical signs) and we established CNA patterns related to BSE in cattle at least 4 months prior to clinical signs. In elk, a progression of CNA sequence patterns was found to precede and correlate with macro-observable disease progression, including delayed CWD progression in elk with PrP genotype LM. Some of the patterns identified contain transcription-factor-binding sites linked to endogenous retroviral integration. These patterns suggest that retroviruses may be connected to the manifestation of TSEs. Our results may become useful for the early diagnosis of TSE in live elk and cattle.

INTRODUCTION

Chronic wasting disease (CWD) was recognized as a naturally occurring transmissible spongiform encephalopathy (TSE) in elk and closely related species nearly 30 years ago (1). Although the causative agent of CWD is still the subject of debate (similar to other TSEs), neuro-invasion of orally challenged elk is thought to primarily occur via the vagosympathetic trunk (2), thus by-passing the blood–brain barrier. The definitive diagnosis of CWD currently involves immunohistochemistry to detect the occurrence of PrPCWD protein in the brain, tonsils and lymph nodes, and histopathology to confirm the presence of spongiform lesions in the brain (3).

Recently, several publications indicate that CNAs might be used to obtain patterns related to diseases such as cancer and stroke (4). It is believed that serum CNAs are related to the lysis of cells in damaged tissues, necrosis and apoptosis (5). In humans, fetal CNAs have been shown to cross the maternal blood–brain barrier (6). It seems likely that CNAs from blood serum are linked to stress-related activities throughout the body, including...
neuronal death associated with TSEs. In the case of TSE, an additional source of CNAs may be exosome-like structures that are expelled by infected cells, as reported for scrapie (7,8). Given the potential benefits of a live blood test, an elk CNA study was undertaken to determine if a correlation exists between CWD and specific CNA pattern distributions in healthy versus diseased animals. In addition, blood CNAs from cattle, which were perorally challenged with BSE and had progressed to approximately 4 months before clinical signs, were investigated by comparison to sham-inoculated animals.

**MATERIALS AND METHODS**

**Elk study**

Twenty-four weaned *Cervus elaphus* females were obtained from two commercial farms in Alberta (Canada). Both farms had no previous cases of CWD, no history of importing animals from herds with CWD, and had been actively participating in CWD surveillance programs. The animals were genotyped and separated into groups, such that both MM and LM animals were distributed over the study period. The rare LL genotype (9) was not present in this study, most likely due to the relatively small number of animals used. The LM genotype is known to be linked with a slower CWD disease progression as compared to the MM genotype (10). The elk were perorally challenged with 10 ml of a 10% brain homogenate (tested for CWD by western blot) and 90% saline (w/v). CWD-positive brain homogenate was obtained from pooled elk tissue, kindly provided by Dr A. Balachandran (Canadian Food Inspection Agency, Fallowfield) and fed to 19 animals. The CWD-negative homogenate was obtained from an elk that died of unrelated causes (Table S1).

**Cattle study**

Serum samples were obtained from 29 Fleckvieh cattle (Simmental breed) 40 months post inoculation, which had been fed 100 g of either PeP^res^-positive brain stem macerate (16 animals) or non-infected brain material (13 animals), respectively (11).

The CNA extraction, DNA sequencing and bioinformatics analysis followed the same protocol in the elk and bovine studies.

**Preparation of sera**

Serum was obtained and prepared as described elsewhere (12). Frozen serum was thawed at 4°C and cell debris was removed by brief centrifugation at 4000 × g for 20 min. The supernatant was subjected to 35 min centrifugation at 20000 × g and the pellet was used for further analyses.

**Nucleic acid extraction, general and CNA-specific amplifications**

The WGA4 GenomePlex® Single Cell Whole Genome Amplification Kit (Sigma) was used for the nucleic-acid extraction and amplification of total nucleic acids according to the manufacturer’s protocol. The amplified DNA was purified and 5 ng DNA of each sample was used for the circulating nucleic-acid-specific amplification using quasi-random primers with a universal 5’ adapter using a proof-reading PCR system.

**Disease-specific CNA subtraction**

PCR products for each animal after oral infection were hybridized with a 10-fold overshoot of biotinylated pre-infection PCR amplicons for 70 h. The latter amplicons contained dUTP for subsequent digestion of unbound products. After binding to strepavidin-coated magnetic beads, followed by magnetic separation, the unbound fraction was collected and subjected to digestion with uracil DNA N-glycosylase to avoid a carry-over of unbound pre-infection amplicons. The remaining undigested PCR-products were used for further processing and sequencing. All pre-infection samples (controls) were used directly for sequencing without any selection.

**DNA sequencing**

The PCR products were sequenced directly using a Roche/454 genome sequencer (GS-FLx) according to the manufacturer’s instructions (conducted at Eurofins-Medigenomix, Martinsried, Germany). The raw sequences were trimmed to eliminate adapter/primer sequences and identification tags.

**Bioinformatics**

Figure 1 provides an overview of the bioinformatics analysis performed. An all-versus-all search of the elk dataset using four TimeLogic DeCypher boards (http://www.timelogic.com) all patterns occurring for a minimum of 20 × (based on the number of infected animals), with none of the top 100 BLAST (13) matches occurring in non-target samples, yielded 10 634 motifs specific to control and infected animals up to 5 months after infection; and 4933 motifs for animals at least 8 months after infection (motifs of 35 bases or less, using a sliding window for longer matches). Each of these motifs was searched against the entire elk CNA dataset using a simulated thermodynamic annealing approach (14). The motifs were further filtered to include only those readily and unambiguously detectable using PCR: i.e. those matching without any critical off-target binding within 4°C under PCR conditions of 10^{-6} M DNA and 0.15 M Na^+. In the two-timepoint bovine dataset, 3261 control-only motifs and 2896 motifs present in infected-only cows were found with the same approach. In addition, each CNA sequence for elk and cattle was searched against the NCBI expressed sequence tag (EST) and non-redundant protein databanks using BLAST to identify potential functions based on sequence similarity.
characteristic exclusively to non-infected elk, we were able to identify a ‘first stage’ motif set, covering animals before clinical signs, up to 5 months post infection. A combination of four individual motifs is needed to capture all of the 24 prebleed (before inoculation) and 28-day/55-day/5-month (post-inoculation) samples. No significant function could be attributed to any of these motifs. Two motifs, which occur only in the near-clinical elk samples, were discovered, hereafter called motifs A and B. The first appearances of motifs A and B in the animals with the MM genotype were at 11 and 13 months; and animals with the LM genotype at 19 and 24 months after inoculation, respectively. Sera sampling and motif occurrence details can be found in Supplementary Table S2. Motif A was found to contain a match to an ecotropic viral integration 1 (EVI1) protein binding site, with 100% core similarity and 95% overall matrix similarity, when searched using the MatInspector database (15). Based on a random sample of 6000 CNAs, we estimate an e-value of 0.01 for any of MatInspector’s EVII patterns in our CNA dataset. Motif B contains a promyelotic leukemia zinc finger (PLZF)-binding site, with 100% core similarity, a 92% overall matrix similarity, and an e-value of ~0.005. In general, the timing of the appearance motifs A and B is dependent on the animals’ genotype and overall health, preceding clinical signs by at least 3 months. A third motif type, motif C, occurs at the terminal stage in all infected animals. This motif does not contain any MatInspector hits as strong as the EVI1 and PLZF indicators. The ‘terminal stage’ motif was also to present at month 8 in a sample of one infected animal, which was sacrificed due to an extensive area of inflammation in the cheek (most likely caused by a skin wound). Oral wounds may greatly accelerate prion neuroinvasion (16), therefore in this case further experimentation is required to determine if this motif is specific to CWD infected-only animals or terminal cases in general.

A total of 595037 quality bovine sequences were elucidated, including 311786 from animals post-infection, with an average read length of 188 bases. In this dataset, four motifs are sufficient to cover all control animals (Table 2). Similar to the elk sample, no significant function could be attributed to any of these motifs (Supplementary Table S2). A search for shared BSE-only motifs demonstrated a high bias towards only one quarter of the 16 animals, making a universal pattern set for BSE harder to obtain. A selection of five motifs is sufficient to detect any of the 16 BSE animals at 40 month, but none of the controls. None of these five BSE-only motifs had statistically significant matches to any known transcription factors. Based on our time series data from elk, the lack of universal sequences in our cattle dataset is not surprising, as indicator motifs tend to appear in the sequence data in low frequency and in a progressive series that is dependent on the health of the individual animals.

In general, reverse transcriptases (pol) genes were well represented in the cattle CNA sequences (Table 3). Several infected animals possessed matches to an uninterrupted pol coding region (Table 3, panel a), while several non-infected animal sequences matched another uninterrupted pol coding region (Table 3, panel b).
Additional retroviral-like sequences with in-frame stop codons are found regardless of infection state (Table 3 panel c). Sequences (a) and (b) from Table 3 may point towards the detectability of BSE-discriminating retroviral patterns, but this will need to be confirmed with a time series study. Using the Smith–Waterman algorithm (17), the reverse transcriptase sequences identified in our samples were found to be more closely related at the protein level to various murine leukemia viruses ($e$-value $10^{-34}$ for the most frequently occurring pol) than to known bovine leukemia viruses ($e$-value $10^{-32}$).

## DISCUSSION

EVI1 is a common site for retroviral integration in mammalian genomes, where viral integration can promote protein expression of EVI1 (18). The EVI1 protein has been shown to act as a transcriptional promoter for a small number of genes, protecting the binding sites

### Table 1. Progressive appearance of CNA motifs exclusive to CWD-infected elk, at least 3 months before clinical signs, and delayed in the CWD-resistant genotype (LM)

| Elk No. | Geno-type | Pre-inoc. | 28d | 55d | 5m | 8m | 11m | 13m | 14m | 15m | 16m | 17m | 18m | 19m | 20m | 21m | 22m | 23m | 24m | 25m |
|---------|-----------|-----------|-----|-----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|
| 35w     | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 24      | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 44      | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 38      | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 99      | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 70      | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 2       | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 93      | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 14      | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 29      | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 26      | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 45      | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 39      | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 19      | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 69      | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 33      | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 27      | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 36y     | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 37      | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 18      | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 28      | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 8       | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 31      | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 6       | MM        |           |     |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |

Motif A contains an EVI1 protein binding site. Motif B contains a PLZF binding site. EVI1 is a known promoter for PLZF. Motif C, which appears at the terminal stage in infected animals, has no known function.

### Table 2. Recurring sequence motifs in BSE-infected and non-infected cattle

| Sequence Motif |
|---------------|
| **Non-infected animals** |
| GGTGGTTGCTGACACCCCTGG |
| CTATAAGATACCCAGGTCCCTGCCCTGGAAGCTC |
| GGAAAGAAGATGGAACAAAGGGCAGCGCAAAAGGC |
| TGCTAGTATGAGTACGCCCTAGGAAATAGCCCTGG |
| **Infected animals** |
| AATCTTAGCTTCTCCATTTGAGGACCAG |
| AAAATCTCGAGCATCTCCCCCAAGAAAACCAG |
| CTGGCAATTCGAGGAGCGTGG |
| AAGAGACCTTGGGGATTCGCTCCCTAGG |
| TGCAACATGCGCCAGCCTCCCCT |

The motifs were discovered using the same technique as used for the elk in Table 1. Serum samples were obtained from 29 Fleckvieh cattle (Simmental breed) 40 months post-inoculation (i.e. at least 4 months before clinical signs).
One pol-like sequence was found exclusively in (5 of 16) infected animals, but may not be endogenous to cattle as it is not found in the current version of the draft bovine genome (13 September 2007). (b) One pol-like sequence was found exclusively in non-infected animals (5 of 13). (c) One gag-like and four pol-like sequences are recurrent in both PrP<sub>res</sub>-infected and non-infected populations, indicating that some endogenous retrovirus sequences are consistently detectable regardless of prion exposure.

from DNAse I digestion (19). The transcription factor’s protective effect (20) may explain the occurrence of motif A in the blood CNAs, especially if EVI1 is being expressed beyond what is normally required for its limited functions in adults (21). One of the genes promoted by EVI1 is the transcription factor PLZF, whose target is found in motif B, thus the function of motifs A and B can be directly linked.

EVI1 expression has thus far not been linked to TSE processes in the literature, but single-stranded RNA retroviruses that preferentially integrate into EVI1 have been. Endogenous murine leukemia virus, which is known to re-integrate into EVI1, has been shown in vivo to replicate upon introduction of scrapie (22). Conversely, Moloney murine leukemia virus infection has been shown in vitro to strongly enhance scrapie infectivity (23). Instances of Moloney-like DNA sequences are also found throughout the latest version of the bovine genome assembly (13 September 2007), with 26 genome regions having a BLAST e-value <10<sup>−100</sup>. Retroviruses may therefore act as cofactors for TSE pathogenesis (24,25). Retrovirus-induced activation of EVI1 during the course of CWD infection could provide a biological basis for the pair of motifs that we detected in elk. These results are also well aligned with our previous findings of human endogenous retroviral associations with progressive neurologic diseases (26).

Growing evidence [e.g. (27,28)] shows that PrP<sub>res</sub> alone has dramatically lower infectivity than TSE agent particles. A link between general retroviral activity and TSEs was first proposed almost twenty years ago (29). While such a link is speculative, two types of data specifically support an endogenous retroviral cofactor theory. First, the prion agent is released into cell culture in association with exosome-like structures and viral particles of endogenous origin (8). Second, a growing body of literature suggests an antiretroviral role for the PrP protein (30–32). More specifically, recent results (32) show that PrP is highly up-regulated in response to increased activity of murine endogenous retroviruses. The mRNA level of PrP also increases after scrapie agent inoculation in lymphoid tissue (33). If PrP<sup>wd</sup>-promoted lymphoid retroviral activity is responsible for EVI1 detection in CNAs, this could explain its early detectability; lymphoid tissues accumulate PrP<sup>wd</sup> before the central nervous system (34).

The nucleic-acid-binding properties of PrP (35), and the presence of PrP<sup>wd</sup> in cervid blood (36) mean that alternative explanations for the presence of the motifs are possible. Retroviral RNA may play a role in the transformation of PrP<sup>Sc</sup> to PrP<sup>Pr</sup> (37), or may conversely reduce PrP<sup>sc</sup> availability (38). While an aptamer role is possible, a Smith–Waterman search of both the motifs and common C-type retroviruses against 87 prion-targeting nucleic-acid aptamers found in the literature and patents does not yield any matches. The possibility remains that the motif sequences may bind PrP in a non-sequence-specific manner (39). A simple present/absent criteria was used for unbiased motif discovery in a randomly sequenced CNA dataset: these motifs will inform our targeted characterization and quantification of disease-specific CNAs and any associated complexes going forward.

The biological mechanism by which the CNAs originate still remains uncertain, but our data support the idea that it is possible to detect host reaction to the CWD and BSE.

---

Table 3. Recurring endogenous retrovirus-like sequences in bovine CNAs

| No. of non-infected animals (no. of total sequence occurrences) | No. of infected animals (no. of total sequence occurrences) | Best homology | Best murine homology | CNA contains stop codon in-frame | Present in bovine genome (>95% DNA ID) |
|---------------------------------------------------------------|---------------------------------------------------------------|---------------|----------------------|---------------------------------|--------------------------------------|
| (a) 0 (0)                                                     | 5 (12)                                                        | 10<sup>−47</sup> gag/pol protein (Populus trichocarpa)   | 10<sup>−14</sup> putative gag-pro-pro polyprotein (murine leukemia virus) | No                               | No                                   |
| (b) 5 (5)                                                     | 0 (0)                                                        | 10<sup>−18</sup> predicted pol polyprotein from transposon 297, partial (Canis familiaris) | 10<sup>−11</sup> pol protein (Recombinant M-MuLV/RaLV retrovirus) | No                               | Truncated match                       |
| 5 (5)                                                         | 3 (3)                                                        | 10<sup>−29</sup> predicted protein (Homo sapiens)        | 10<sup>−23</sup> polymerase (murine leukemia virus) | No                               | Truncated match                       |
| 2 (2)                                                         | 5 (4)                                                        | 10<sup>−37</sup> gag protein (Bos taurus)                | 10<sup>−10</sup> gag polyprotein (murine leukemia virus) | No                               | Yes                                  |
| (c) 2 (4)                                                      | 4 (5)                                                        | 10<sup>−23</sup> pol protein (human endogenous retrovirus HCML-ARV) | 10<sup>−19</sup> gag-pol polyprotein (murine leukemia virus) | Yes                              | Truncated match                       |
| 5 (7)                                                         | 8 (10)                                                       | 10<sup>−89</sup> polyprotein (multiple sclerosis associated retrovirus) | 10<sup>−34</sup> pol polypeptide (murine leukemia virus) | Yes                              | Yes                                  |
| 2 (2)                                                         | 3 (3)                                                        | 10<sup>−8</sup> pol protein (human endogenous retrovirus HCML-ARV) | 10<sup>−6</sup> pol polypeptide (murine leukemia virus) | Yes                              | Yes                                  |
infectious agents via CNAs in live animals, and importantly, before clinical signs appear. Further studies will help to validate the specificity of patterns for TSEs versus brain trauma and other neurological diseases, as well as the consistency of the patterns in naturally occurring CWD and BSE cases. The information from the elk study demonstrates that a time course analysis of the blood CNAs can greatly improve our ability to determine the diagnostic signals present in slowly developing, poorly understood diseases such as TSEs. We consider that the patterns described here provide a starting point for the development of a relatively simple, cost-effective live animal test. For instance, in the future PCR-based tests, pooled samples could be used on a large scale to eliminate infected animals from the human food chain, even before the onset of clinical signs. In this context, it is also interesting that we were able to identify a combination of patterns in elk, which was only found in control animals and animals up to 5 months after infection, and patterns in cattle that were only present in the controls (when compared to animals 40 months after infection). Adding these patterns to the eventual screening strategy could certainly enhance the accuracy of a live animal testing system.

SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.

ACKNOWLEDGEMENTS
We thank Sara Hennecke and Stefan Balzer (Chronix Biomedical GmbH) for their skilful technical assistance, Dr. Sascha Glinka and Dr Birgit Ottenwälder at Eurofins Medigenomix GmbH (Munich, Germany) for performing the GSFLX/454 sequencing. The authors would also like to thank Dr Marvin Fritzler, University of Calgary for the critical reading of the manuscript and his suggestions.

FUNDING
The elk study was funded partly by a core grant of the Alberta Prion Research Institute. The cattle work was supported in part by the German ‘Bundesministerium für Ernährung, Landwirtschaft und Verbraucherschutz’, the German ‘Bundesministerium für Bildung, Wissenschaft und Technologie’ and the EU commission through the Network of Excellence ‘Neuroprion’. J.B. and parts of the cattle studies were funded by a grant of the German ‘Bundesministerium für Bildung und Forschung’ (BioProfil FKZ 0313859 BioP-es2004 to E.S.). Funding the Network of Excellence ‘Neuroprion’. J.B. and parts of the cattle studies were funded by a grant of the German ‘Bundesministerium für Bildung und Forschung’ (BioProfil FKZ 0313859 BioP-es2004 to E.S.). Funding the Network of Excellence ‘Neuroprion’. J.B. and parts of the cattle studies were funded by a grant of the German ‘Bundesministerium für Bildung und Forschung’ (BioProfil FKZ 0313859 BioP-es2004 to E.S.).

REFERENCES
1. Williams,E.S. and Young,S. (1980) Chronic wasting disease of captive mule deer: a spongiform encephalopathy. J. Wildl. Dis., 16, 89–98.

2. Sigurdson,C.J., Spraker,T.R., Miller,M.W., Oesch,B. and Hoover,E.A. (2001) PrPCDW in the myenteric plexus, vagosympathetic trunk and endocrine glands of deer with chronic wasting disease. J. Gen. Virol., 82, 2327–2334.

3. Williams,E.S., Miller,M.W., Kreeger,T.J., Kahn,R.H. and Thorne,E.T. (2002) Chronic wasting disease of deer and elk: a review with recommendations for management. J. Wildl. Manag., 66, 551–563.

4. Swarup,V. and Rajeswari,M.R. (2007) Circulating (cell-free) nucleic acids – a promising, non-invasive tool for early detection of several human diseases. FEBS Lett., 581, 795–7994.

5. Stroun,M., Maurice,P., Vasioukhin,V., Lyautey,J., Lederrey,C., Lefort,F., Rossier,A. and Perucchini,M. (2006) The origin and mechanism of circulating DNA. Ann. NY Acad. Sci., 1061, 161–168.

6. Wataganara,T. and Bianchi,D.W. (2004) Fetal Cell-Free Nucleic Acids in the Maternal Circulation: New Clinical Applications. Ann. NY Acad. Sci., 1022, 90–99.

7. Fevrier,B., Vilette,D., Archer,F., Loew,D., Faigle,W., Vidal,M., Laude,H. and Raposo,G. (2004) Cells release prions in association with exosomes. Proc. Natl Acad. Sci. USA, 101, 9683–9688.

8. Alais,S., Simoes,S., Baas,D., Lehnmann,S., Raposo,G., Darlix,J.L. and Leblanc,P. (2008) Mouse neuroblastoma cells release prion infectivity associated with exosomal vesicles. Biol. Cell, 100, 603–615.

9. Peruczini,M., Grillon,K., Miller,M.W. and Goldmann,W. (2008) PrP genotypes of free-ranging wapiti (Cervus elaphus nelsoni) with chronic wasting disease. J. Gen. Virol., 89, 1324–1328.

10. Green,M.A., Williams,E., Macro,E. and Lypautey,C. (2007) The oncogene and developmental regulator Evi1: a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein. EMBO J., 198, 1048–1055.

11. Hoffmann,C., Ziegler,U., Buschmann,A., Weber,A., Kupfer,A., Oeschlegel,A., Hammerschmidt,M. and Groschup,H.M. (2007) Prions spread via the autonomic nervous system from the gut to the central nervous system in cattle incubating bovine spongiform encephalopathy. J. Gen. Virol., 88, 598–608.

12. Schütz,E., Uornovitz,H.B., Iakoubov,L., Schulz-Schaefler,W., Wemheuer,W. and Brengig,B. (2005) Bov-IA short interspersed nucleotide element sequences in circulating nucleic acids from sera of cattle with bovine Spongiform Encephalopathy (BSE) and sera of cattle exposed to BSE. Clin. Diagn. Lab. Immunol., 12, 814–820.

13. Altschul,S.F., Gish,W., Miller,W., Myers,E. and Lipman,D.J. (1990) Basic local alignment search tool. J. Mol. Biol., 215, 403–410.

14. Gordon,P.M.K. and Sensen,C.W. (2004) Osprey: a comprehensive tool employing novel methods for the design of oligonucleotides for DNA sequencing and microarrays. Nucleic Acids Res., 32, e133.

15. Carp,R.I., Meeker,H.C., Caruso,V. and Sensen,E. (1999) Sapric strain-specific interactions with endogenous murine leukemia virus. J. Gen. Virol., 80, 5–10.

16. Bartz,J.C., Kincaid,A.E. and Bessen,R.A. (2003) Rapid Prion Neuroinvasion following Tongue Infection. J. Virol., 77, 583–591.

17. Smith,T.F. and Waterman,M.S. (1981) Identification of common molecular subsequences. J. Mol. Biol., 215, 195–197.

18. Wieser,R. (2007) The oncogene and developmental regulator Evi1 enhances scrapie infectivity release in cell culture. J. Gen. Virol., 88, 2674–2685.

19. Bartz,J.C., Kincaid,A.E. and Bessen,R.A. (2003) Rapid Prion Neuroinvasion following Tongue Infection. J. Virol., 77, 583–591.

20. Smith,T.F. and Waterman,M.S. (1981) Identification of common molecular subsequences. J. Mol. Biol., 215, 195–197.

21. Yatsula,B., Lin,S., Read,A.J., Poholek,A., Yue,D., Hui,P. and Goldmann,W. (2008) Mouse neuroblastoma cells release prion infectivity associated with exosomal vesicles. Biol. Cell, 100, 603–615.

22. Carp,R.I., Meeker,H.C., Caruso,V. and Sensen,E. (1999) Sapric strain-specific interactions with endogenous murine leukemia virus. J. Gen. Virol., 80, 5–10.

23. Leblanc,P., Alais,S., Porto-Carreiro,I., Lehnmann,S., Grass,J., Raposo,G. and Darlix,J.L. (2006) Retrovirus infection strongly enhances sapric infectivity release in cell culture. EMBO J., 25, 2674–2685.
24. Stengel, A., Bach, C., Vorberg, I., Frank, O., Gilch, S., Lutzny, G., Seifarth, W., Erflé, V., Maas, E., Schätzl, H. et al. (2006) Prion infection influences murine endogenous retrovirus expression in neuronal cells. *Biochem. Biophys. Res. Commun.*, 343, 825–831.

25. Lee, K.H., Jeong, B.H., Jin, J.K., Meeker, H.C., Kim, J.I., Carp, R.I. and Kim, Y.-S. (2006) Scrapie infection activates the replication of ecotropic, xenotropic, and polytropic murine leukemia virus (MuLV) in brains and spinal cords of senescence-accelerated mice: Implication of MuLV in progression of scrapie pathogenesis. *Biochem. Biophys. Res. Commun.*, 349, 122–130.

26. Urnovitz, H.B. and Murphy, W.H. (1996) Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease. *Clin. Microbial Rev.*, 9, 72–99.

27. Sun, R., Liu, Y., Zhang, H. and Manuelidis, L. (2008) Quantitative recovery of scrapie agent with minimal protein from highly infectious cultures. *Viral Immunol.*, 21, 293–302.

28. Arjona, A., Simarro, L., Islinger, F., Nishida, N. and Manuelidis, L. Two Creutzfeldt-Jakob disease agents reproduce prion protein-independent identities in cell cultures. *Proc. Natl Acad. Sci. USA*, 101, 8768–8773.

29. Murdoch, G.H., Sklaviadis, T., Manuelidis, E.E. and Manuelidis, L. (1990) Potential retroviral RNAs in Creutzfeldt-Jakob disease. *J. Virol.*, 64, 1477–1486.

30. Gabus, C., Auxilien, S., Pechoux, C., Dormont, D., Swietnicki, W., Morillas, M., Surewicz, W., Nandi, P. and Darlix, J.-L. (2001) The prion protein has DNA strand transfer properties similar to retroviral nucleocapsid protein. *J. Mol. Biol.*, 307, 1011–1021.

31. Leblanc, P., Baas, D. and Darlix, J.-L. (2004) Analysis of the Interactions Between HIV-1 and the cellular prion protein in a human cell line. *J. Mol. Biol.*, 337, 1035–1051.

32. Lötischer, M., Recher, M., Lang, K.S., Navarini, A., Hunziker, L., Santimaria, R., Glatzel, M., Schwarz, P., Böni, J. and Zinkernagel, R.M. (2007) Induced prion protein controls immune-activated retroviruses in the mouse spleen. *PLoS One*, 2, e1158.

33. Austbo, L., Espenes, A., Olsaker, I., Press, C.M. and Skretting, G. (2007) Increased PrP mRNA expression in lymphoid follicles of the ileal Peyer's patch of sheep experimentally exposed to the scrapie agent. *J. Gen. Virol.*, 88, 2083–2090.

34. Fox, K.A., Jewell, J.E., Williams, E.S. and Miller, M.W. (2006) Patterns of PrPCWD accumulation during the course of chronic wasting disease infection in orally inoculated mule deer (Odocoileus hemionus). *J. Gen. Virol.*, 87, 3451–3461.

35. Silva, J.L., Lima, L.M., Fouguel, D. and Cordeiro, Y. (2008) Intriguing nucleic-acid-binding features of mammalian prion protein. *Trends Biochem. Sci.*, 33, 132–140.

36. Mathiason, C.K., Powers, J.G., Dahmes, S.J., Osborn, D.A., Miller, K.V., Warren, R.J., Mason, G.L., Hays, S.A., Hayes-Klug, J., Seelh, D.M. et al. (2006) Infectious prions in the saliva and blood of deer with chronic wasting disease. *Science*, 314, 133–136.

37. Deleault, N.R., Lucassen, R.W. and Supattapone, S. (2003) RNA molecules stimulate prion protein conversion. *Nature*, 425, 717–720.

38. Proske, D., Gilch, S., Wopfner, F., Schätzl, H.M., Winnacker, E.L. and Famulok, M. (2002) Prion-protein-specific aptamer reduces PrPSc formation. *ChemBioChem.*, 3, 717–725.

39. King, D.J., Safar, J.G., Legname, G. and Prusiner, S.B. (2007) Thioaptamer interactions with prion proteins: sequence-specific and non-specific binding sites. *J. Mol. Biol.*, 369, 1001–1014.